



Ref: NEPHROPLUS/SE/79

August 17, 2026

To
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
Scrip Code: 544647
Through: BSE Listing Centre

To
National Stock Exchange of India Limited
5th Floor, Exchange Plaza, Bandra (E),
Mumbai – 400 051
Scrip Symbol: NEPHROPLUS
Through: NEAPS

Subject: Disclosure under Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“**SEBI Master Circular**”), we hereby inform that Nephrocare Health Care Services, Philippines Inc., an overseas step-down wholly-owned subsidiary of Nephrocare Health Services Limited (“**the Company**”), has entered into an Asset Transfer Agreement (“**ATA**”) dated August 14, 2026 and has been executed on August 17, 2026 with Assumption Dialysis Center for the acquisition of identified assets relating to a dialysis center located at Daang Maharlika, Brgy. Bunga, Abuyog, Leyte, Philippines, for a total consideration of PhP 75,000,000 (Philippine Pesos Seventy-Five Million Only), subject to the terms and conditions set out therein.

The details as required under Regulation 30 of the SEBI Listing Regulations read with the aforesaid SEBI Master Circular are enclosed herewith as **Annexure I**.

The aforesaid information is also being made available on the Company’s website at www.nephroplus.com.

For Nephrocare Health Services Limited
(Formerly Nephrocare Health Services Private Limited)

Kishore Kathri
Company Secretary & Head Legal
ICSI M. No. F9895



ANNEXURE I

Sr. No	Particulars	Description
1.	Name(s) of parties with whom the agreement is entered	Nephrocare Health Care Services, Philippines Inc. (an overseas step-down wholly-owned subsidiary of the Company) (" Purchaser ") and Assumption Dialysis Center (" Seller ")
2.	Purpose of entering into the agreement	Acquisition of the dialysis center assets pursuant to the Asset Transfer Agreement (the " Transaction "), in accordance with and subject to the terms and conditions stipulated therein.
3.	Size of agreement	PhP 75,000,000.00 (Philippine Pesos Seventy-Five Million Pesos Only)
4.	Shareholding, if any, in the entity with whom the agreement is executed	Not Applicable
5.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	There are no special rights as per the agreements.
6.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	Purchaser is an overseas step-down wholly owned subsidiary of the Company. Seller is not related.
7.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	No
8.	In case of issuance of shares to the parties, details of issue price, class of shares issued;	Not applicable
9.	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security	Not Applicable

Nephrocare Health Services Limited (Global Corporate Headquarters)

(Formerly Nephrocare Health Services Private Limited)

5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500 081, Telangana, India.

+91 40 4240 8039 contactus@nephroplus.com www.nephroplus.com

CIN: L85100TG2009PLC066359 | GSTIN: 36AADCN1504A1Z8 | ISD GST: 36AADCN1504A2Z7

	provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis;	
10.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Not Applicable
11.	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a. Name of parties to the agreement; b. Nature of the agreement; c. Date of execution of the agreement; d. Details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable